Last update Aug. 29, 2021

Eptifibatide

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Hexapeptide that binds to the platelet glycoprotein receptor, inhibiting its aggregation by preventing its binding to fibrinogen and other clotting factors such as von Willebrand factor.
Indicated for the prevention of early myocardial infarction in adults with unstable angina.
Intravenous administration.

At the date of the last update, there was no available published data on its excretion in breast milk.

Its high molecular weight makes it difficult to excrete in breast milk.

Due to its protein nature, it is inactivated in the gastrointestinal tract, not being absorbed (practically nil oral bioavailability), which hinders or prevents the passage into plasma of the infant from ingested breast milk except in the premature and during the immediate neonatal period, during which there may be increased intestinal permeability.

Alternatives

  • Aspirin (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Eptifibatide is also known as


Group

Eptifibatide belongs to this group or family:

Tradenames

Main tradenames from several countries containing Eptifibatide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 832 daltons
Protein Binding 25 %
VD 0,18 - 0,26 l/Kg
Tmax 0,1 hours
T1/2 2,5 hours

References

  1. EMA. Eptifibatida. Ficha técnica. 2016 Full text (in our servers)
  2. EMA. Eptifibatide. Drug Summary. 2016

Total visits

2,305

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM